| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
3 |
| Employees |
34 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
1,236 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Enlivex Therapeutics Ltd is a clinical-stage biotechnology company that focuses on developing novel therapies for immune system disorders. The company is known for its flagship product, Allocetra, which is a cell-based immunotherapy designed to rebalance the immune system and restore its proper function.
Enlivex's approach is based on the understanding that many diseases, such as sepsis, graft-versus-host disease, and solid tumors, result from an imbalance in the immune system. Allocetra addresses this imbalance by selectively targeting excessive immune responses while leaving the beneficial immune functions intact.
The company has conducted several clinical trials to evaluate the safety and efficacy of Allocetra in various indications. The results have shown promising outcomes, leading to collaborations with leading medical centers and biopharmaceutical companies.
Enlivex is committed to advancing its product pipeline and developing innovative therapies to address unmet medical needs. The company is driven by the goal of improving patients' quality of life and transforming the management of immune system disorders.
Company Address: 14 Einstein Street Ness Ziona 7403618
Company Phone Number: 2.6208072 Stock Exchange / Ticker: NASDAQ ENLV
|
2.95%